Associate Professor of Hepatology
Thomas Reiberger obtained his MD at the Medical University of Vienna in 2005. After a first postdoc at the Department of Pathophysiology at the Medical University of Vienna focusing on ex-situ liver perfusion and liver cell biology he completed his residency for Internal Medicine at the Divison of Gastroenterology and Hepatology. He persued a career of a physician scientist by performing translational clinial studies on portal hypertension and fibrosis in patients with various etiologies of liver disease. Next to his clinical engagement, he established the Vienna Hepatic Experimental (HEPEX) Lab at the Medical University of Vienna. In 2011, he received his Venia docendi. After another postdoctoral fellowship in the United States, Thomas Reiberger was appointed as Associate Professor of Gastroenterology and Hepatology at the Medical University of Vienna. He conducted seminal studies for optimizing the role of non-selective betablocker therapy in patients with cirrhosis and portal hypertension. The main mission of his HEPEX research team is the exploration of novel treatment options for liver fibrosis and portal hypertensions. Since 2018 Thomas Reiberger is also the director of the cirrhosis clinic and the Hepatic Hemodynamic Lab at the Medical University of Vienna.